R24 (ATCC® HB-8445)

Organism: Mus musculus (B cell); Mus musculus (myeloma), mouse (B cell); mouse (myeloma)  /  Cell Type: hybridoma: B lymphocyte  / 

Permits and Restrictions

View Permits View Restrictions

Organism Mus musculus (B cell); Mus musculus (myeloma), mouse (B cell); mouse (myeloma)
Cell Type hybridoma: B lymphocyte
Product Format frozen
Morphology lymphoblast
Culture Properties suspension, suspension
Biosafety Level 1

Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country.

The antibody reacts with the M-18 antigen system.
Disclosure This material is cited in a US or other Patent and may not be used to infringe the claims. Depending on the wishes of the Depositor, ATCC may be required to inform the Patent Depositor of the party to which the material was furnished. This material may not have been produced or characterized by ATCC.
Spleen cells were fused with NS-1 myeloma cells.
Genes Expressed
immunoglobulin; monoclonal antibody; against a human melanoma cell line (M-18 antigen system)
Cellular Products
immunoglobulin; monoclonal antibody; against a human melanoma cell line (M-18 antigen system)
Animals were immunized with the SK-MEL-28 human melanoma cell line.
Spleen cells were fused with NS-1 myeloma cells.
The antibody reacts with the M-18 antigen system.
Complete Growth Medium The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, ATCC 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum (ATCC 30-2020) to a final concentration of 10%.
Complete Growth Medium
Culture Medium: RPMI 1640 with 2.0 mM L-glutamine adjusted to contain 1.5 g/L
sodium bicarbonate, 4.5 g/L glucose, 10.0 mM HEPES, and 1.0 mM sodium pyruvate,
90%; fetal bovine serum, 10%.
Medium Renewal: Every 2 to 3 days
Cultures can be maintained by addition or replacement of fresh medium. Start cultures at 2 X 10 exp5 cells/ml and maintain between 1 X 10 exp5 and 1 X 10 exp6 cells/ml.
culture medium, 90%; DMSO, 10%
Culture Conditions
Temperature: 37.0°C
Isotype IgG3
Notice: Necessary PermitsPermits

These permits may be required for shipping this product:

  • Customers located in the state of Hawaii will need to contact the Hawaii Department of Agriculture to determine if an Import Permit is required. A copy of the permit or documentation that a permit is not required must be sent to ATCC in advance of shipment.
Basic Documentation

The cells are distributed for research purposes only. The Memorial Sloan-Kettering Cancer Center releases the line subject to the following: 1.) The cells or their products must not be distributed to third parties. Commercial interests are the exclusive property of Memorial Sloan-Kettering Cancer Center. 2.) Any proposed commercial use of these cells must first be negotiated with The Director, Office of Industrial Affairs, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021; phone (212) 639-6181; FAX (212) 717-3439.


Houghton AN, et al. Surface antigens of melanocytes and melanomas. Markers of melanocyte differentiation and melanoma subsets. J. Exp. Med. 156: 1755-1766, 1982. PubMed: 7175440

Real FX, et al. Surface antigens of melanomas and melanocytes defined by mouse monoclonal antibodies: Specificity analysis and comparison of antigen expression in cultured cells and tissues. Cancer Res. 45: 4401-4411, 1985. PubMed: 4028024

Cairncross JG, et al. Monoclonal antibodies against melanocytes. US Patent 4,806,628 dated Feb 21 1989

Oettgen HF, et al. Monoclonal antibodies to cell surface antigens of human malignant melanoma. US Patent 4,808,704 dated Feb 28 1989

Dippold WG, et al. Inhibition of human melanoma cell growth in vitro by monoclonal anti- GD3-ganglioside antibody. Cancer Res. 44: 806-810, 1984. PubMed: 6362854

Dippold WG, et al. Melanoma antibodies: specificity and interaction with melanoma and cytotoxic T-cells. Behring Inst. Mitt. 74: 14-18, 1984. PubMed: 6332614

Graus F, et al. Distribution of the ganglioside GD3 in the human nervous system detected by R24 mouse monoclonal antibody. Brain Res. 324: 190-194, 1984. PubMed: 6394100

. . Eur. J. Clin. Oncol. 21: 907-912, 1985.

Dippold WG, et al. Cell surface antigens of human malignant melanoma: definition of six antigenic systems with mouse monoclonal antibodies. Proc. Natl. Acad. Sci. USA 77: 6114-6118, 1980. PubMed: 6934537

Houghton AN, et al. Mouse monoclonal IgG3 antibody detecting GD3 ganglioside: a phase I trial in patients with malignant melanoma. Proc. Natl. Acad. Sci. USA 82: 1242-1246, 1985. PubMed: 3883355

Pukel CS, et al. GD3, a prominent ganglioside of human melanoma. Detection and characterisation by mouse monoclonal antibody. J. Exp. Med. 155: 1133-1147, 1982. PubMed: 7061953

Shi WX, et al. Regulation of sialic acid 9-O-acetylation during the growth and differentiation of murine erythroleukemia cells. J. Biol. Chem. 49: 31517-31525, 1996. PubMed: 8940167